Welcome to our dedicated page for BXRX news (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on BXRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BXRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BXRX's position in the market.
On March 3, 2022, Baudax Bio (NASDAQ:BXRX) announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This compliance was determined after the company's stock closed above $1.00 for 10 consecutive business days from February 16 to March 2, 2022. The matter is now considered closed by Nasdaq. Baudax Bio focuses on innovative products for acute care, with its lead product, ANJESO, being the first and only 24-hour IV COX-2 preferential NSAID for managing moderate to severe pain.
Baudax Bio, Inc. (NASDAQ:BXRX) announced the issuance of United States Patent No. 11,253,478 for its product ANJESO, covering new injectable meloxicam compositions. This patent, expiring in May 2030, reinforces exclusivity for ANJESO, which now has a total of six patents listed in the FDA's Orange Book. The patent aims to create a barrier against generic competitors. ANJESO is indicated for managing moderate to severe pain without the risks associated with opioids, backed by extensive clinical trials.
Baudax Bio (NASDAQ: BXRX) announced the pricing of a public offering of 3,508,772 shares of common stock, alongside warrants for the same amount. The offering is priced at $2.85 per share, with an expected gross proceeds of approximately $10 million before expenses. The warrants have an exercise price of $3.25 and will expire in five years. The funds are intended for the commercialization of ANJESO, pipeline development, and general corporate purposes. The offering is set to close around March 1, 2022, subject to customary conditions.
Baudax Bio (NASDAQ: BXRX) has initiated a proposed underwritten public offering of its common stock and warrants. The offering is intended to raise funds for the commercialization of ANJESO, pipeline development, and general corporate purposes. The offering is subject to market conditions, and a preliminary prospectus has been filed with the SEC. H.C. Wainwright & Co. is acting as the sole book-running manager. The company emphasizes that there is no assurance of completion or specific terms of the offering.
Baudax Bio (NASDAQ:BXRX) announced a 1-for-35 reverse stock split, effective February 16, 2022, to comply with Nasdaq's $1.00 minimum bid price requirement. The split reduces outstanding shares from approximately 101.6 million to about 2.9 million, maintaining par value at $0.01 per share. Shareholders will receive cash for any fractional shares. This move aims to enhance the stock's market price and attract new investors, with adjustments made to outstanding stock options and warrants.
MALVERN, Pa., Jan. 4, 2022 - Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation will be available for on-demand listening starting January 10, 2022, at 7:00 a.m. ET on the company's website, with a replay available for 30 days afterward.
Baudax Bio specializes in developing innovative products for acute care, including ANJESO, a unique 24-hour intravenous NSAID for managing moderate to severe pain, alongside a promising pipeline of neuromuscular blocking agents.
Baudax Bio (NASDAQ:BXRX) announced on December 31, 2021, that its Compensation Committee approved stock option grants totaling 109,250 shares and restricted stock units covering 31,900 shares to 14 newly-hired employees. These grants, effective December 29, 2021, are compliant with Nasdaq Rule 5635(c)(4), serving as inducements for employment. The options will have an exercise price of $0.22 per share, vesting over four years. Baudax Bio focuses on acute care products and is known for ANJESO, the first IV COX-2 preferential NSAID for pain management.
Baudax Bio (NASDAQ:BXRX) has announced a definitive agreement to sell 42,289.3 shares of convertible preferred stock and warrants for gross proceeds of $4.2 million. The preferred stock, convertible into 16,915,720 shares of common stock at $0.25 each, and warrants at $0.32, aim to support the commercialization of ANJESO and other pipeline activities. The transaction, expected to close on December 28, 2021, involves the establishment of voting rights, enabling preferred stockholders to influence decisions on a proposed reverse stock split.
MALVERN, Pa., Nov. 15, 2021 - Baudax Bio, a pharmaceutical company focused on developing innovative acute care products, announced that its CEO Gerri Henwood will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The chat will be available for on-demand listening starting November 22, 2021, at 10:00 a.m. ET on the company's website. Baudax Bio's lead product, ANJESO, is the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain.
Baudax Bio (NASDAQ:BXRX) announced the completion of a dose-escalation study for BX-1000, an intermediate-duration neuromuscular blocking agent (NMB), which was generally well tolerated. The study involved 58 healthy volunteers and monitored rapid muscle paralysis and subsequent recovery. The company is preparing to submit a clinical study report to the FDA and plans to advance BX-2000 and BX-3000 into clinical studies in 2022, after completing toxicology studies. These NMBs can reduce recovery times in surgical settings, promising significant cost savings for healthcare facilities.
